{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:45:23Z","timestamp":1787136323347,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtha.2024.03.022","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T16:44:59Z","timestamp":1712421899000},"page":"1857-1866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A"],"prefix":"10.1016","volume":"22","author":[{"given":"Laurie","family":"Josset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Leuci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maissaa","family":"Janbain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00eblle","family":"De-Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Desage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lienhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Lebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.03.022_bib1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.022_bib3","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12887-022-03546-1","article-title":"Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab","volume":"22","author":"Glonnegger","year":"2022","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jtha.2024.03.022_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a paediatric cohort: real-world data","volume":"191","author":"Barg","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A\u00a0hemophilia A mouse model for the in\u00a0vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.022_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with Factor\u00a0VIII Inhibitors: HAVEN 1 Study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in\u00a0vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.022_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbatista","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib11","doi-asserted-by":"crossref","first-page":"E285","DOI":"10.1002\/ajh.27039","article-title":"Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: real-world retrospective multi-institutional cohort","volume":"98","author":"Batsuli","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.25153","article-title":"Shifting landscape of hemophilia therapy: implications for current clinical laboratory coagulation assays","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12725","article-title":"Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: a method validation study","volume":"6","author":"Donners","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib15","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1124\/dmd.114.058917","article-title":"Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry","volume":"42","author":"An","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jtha.2024.03.022_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1055\/s-0043-1769788","article-title":"Pharmacodynamics monitoring of emicizumab in patients with hemophilia A","volume":"123","author":"Bertaggia Calderara","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemos Thromb"},{"key":"10.1016\/j.jtha.2024.03.022_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115163","article-title":"Development of simple and rapid method for Emicizumab quantification by LC-MS\/MS in human plasma","volume":"223","author":"Josset","year":"2023","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jtha.2024.03.022_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14679","article-title":"Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A","volume":"29","author":"Schmitt","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib22","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.022_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hae.13493","article-title":"Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq \u00ae (human-cl rhFVIII) in previously treated patients with severe haemophilia A","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia \u2013 an in\u00a0vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hae.14684","article-title":"Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in\u00a0vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab","volume":"29","author":"Kizilocak","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib26","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.022_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.19.1.170","article-title":"Thrombin activates factor XI on activated platelets in the absence of factor XII","volume":"19","author":"Oliver","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.03.022_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2023.01.007","article-title":"In\u00a0vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab","volume":"222","author":"Yamaguchi","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.03.022_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","article-title":"Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity","volume":"111","author":"Kitazawa","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.03.022_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"Wolberg","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.03.022_bib31","first-page":"1836","article-title":"Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc","volume":"109","author":"Sefiane","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.03.022_bib32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/FTD.0000000000000571","article-title":"Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases","volume":"41","author":"Dreesen","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jtha.2024.03.022_bib34","doi-asserted-by":"crossref","first-page":"e00545","DOI":"10.1128\/CVI.00545-16","article-title":"Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory","volume":"24","author":"Ladwig","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jtha.2024.03.022_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1373\/clinchem.2015.248146","article-title":"Effective use of mass spectrometry in the clinical laboratory","volume":"62","author":"Jannetto","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2024.03.022_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib37","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/hae.14264","article-title":"Approximation of emicizumab plasma levels in emergency situations. A practical approach","volume":"27","author":"Pekrul","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.03.022_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462489","article-title":"A\u00a0generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry","volume":"1655","author":"Amrani","year":"2021","journal-title":"J\u00a0Chromatogr A"},{"key":"10.1016\/j.jtha.2024.03.022_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A\u00a0prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11","author":"Krishnaswamy","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib41","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","article-title":"Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives","volume":"121","author":"Young","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.022_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/rth2.12295","article-title":"Global coagulation assays in hemophilia A: a comparison to conventional assays","volume":"4","author":"Aghighi","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.022_bib43","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:03:25Z","timestamp":1751371405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1538783624001818"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}